Mejoras tecnológicas en las válvulas que se traducen en resultados clínicos

Technological Improvements in Valves Translate into Clinical Results

Three generations of self-expanding valves, three different prognoses for our patients. Design improvements and better materials in self-expanding, supra-annular aortic valves, and their better results, have allowed for the expansion of the indication for transcatheter aortic valve replacement (TAVR). Particularly, the addition of a pericardial skirt improves annular sealing and results in a significantly low<a href="https://solaci.org/en/2020/04/08/technological-improvements-in-valves-translate-into-clinical-results/" title="Read more" >...</a>

Estenosis aórtica moderada y disfunción ventricular ¿debería apurarse la indicación del recambio?

Treating Both Atrial Valves Improves Survival

Courtesy of Dr. Carlos Fava. There a few treatment options for tricuspid valve disease. It is practically limited to diuretics and surgery, is associated to high mortality and, generally, mitral regurgitation.  Developing the “edge-to-edge” strategy with MitraClip has been shown beneficial and, at present, there are studies that claim this technique could be greatly beneficial<a href="https://solaci.org/en/2020/03/10/treating-both-atrial-valves-improves-survival/" title="Read more" >...</a>

Evaluación Hemodinámica de la Insuficiencia Aórtica post TAVR

Medical vs. Endovascular Treatment in Uncomplicated Type B Aortic Dissection

Under much debate, the treatment of uncomplicated type B aortic dissection is still uncertain. Several studies with methodological limitations have shown that endovascular treatment plus optimal medical treatment might be beneficial, compared with medical treatment alone. This meta-analysis sought to define more clearly the treatment strategy in patients with acute and subacute uncomplicated type B<a href="https://solaci.org/en/2020/01/21/medical-vs-endovascular-treatment-in-uncomplicated-type-b-aortic-dissection/" title="Read more" >...</a>

Agreement between SOLACI and the Journal of Structural Heart Disease

It is with great pleasure that SOLACI announces an agreement with the Journal of Structural Heart Disease. From now on, all readers, users and members of SOLACI will be able to access the contents of this prestigious publication from our website. Click on the section “Publications”> “Other Magazines” of our website, and there you can<a href="https://solaci.org/en/2019/12/06/agreement-between-solaci-and-the-journal-of-structural-heart-disease/" title="Read more" >...</a>

Temporal Trends and Outcomes of TAVR in Bicuspids: Are We Any Better?

This large registry has shown bicuspid aortic stenosis (AS) patients have similar mortality with transcatheter aortic valve replacement (TAVR) compared against surgical valve replacement (SAVR). TAVR outcomes in this population are not only similar to SAVR outcomes, but also to TAVR outcomes in patients with conventional aortic valve anatomy. Despite the good news, these outcomes<a href="https://solaci.org/en/2019/11/15/temporal-trends-and-outcomes-of-tavr-in-bicuspids-are-we-any-better/" title="Read more" >...</a>

TAVR and Pacemakers, New Strategies

Courtesy of Dr. Carlos Fava. TAVR has been shown beneficial and is constantly being advanced onto lower risk populations, but at present, it is limited (perhaps most importantly in aortic tricuspid valves) by the need for permanent pacemaker implantation (PPMI), especially when it comes to self-expandable valves, as the latest study on low risk populations<a href="https://solaci.org/en/2019/09/30/tavr-and-pacemakers-new-strategies/" title="Read more" >...</a>

El reemplazo transcatéter en válvulas bicúspides suma evidencia pero continúan los desafíos

TAVR in Bicuspid Has the Same Results in Surgery at Hospital Level

Courtesy of Dr. Carlos Fava. Bicuspid aortic stenosis patients (bicuspid AS) represent a small group and have not been included in the larger transcatheter aortic valve replacement (TAVR) studies, since they present different morphology and asymmetric calcification, which might come along with more paravalvular leak and less accurate positioning. Between 2012 and 2016, 475,315 patients<a href="https://solaci.org/en/2019/09/24/tavr-in-bicuspid-has-the-same-results-in-surgery-at-hospital-level/" title="Read more" >...</a>

The Most Read Articles of August in solaci website

1-FDA Expands TAVR Indication to Low-Risk Patients Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization to be indicated for low-risk patients in a long-awaited announcement made on August 16th, 2019. Read also HERE 2-Mechanisms of Post PCI Persistent Angina Angina persistence or recurrence after PCI can<a href="https://solaci.org/en/2019/09/16/the-most-read-articles-of-august-in-solaci-website/" title="Read more" >...</a>

ESC 2019 | Complete: La evidencia definitiva para infartos con múltiples vasos

ESC 2019 | COMPLETE: Definitive Evidence for Infarction with Multivessel Disease

For patients with ST-segment elevation acute myocardial infarction and multivessel disease beyond the culprit artery, complete revascularization is superior to culprit-only treatment as regards the final endpoint, a composite of cardiovascular death, infarction, and ischemia-driven revascularization over a mean follow-up of 3 years. This information derives from long-awaited randomized study COMPLETE, finally presented at the<a href="https://solaci.org/en/2019/09/05/esc-2019-complete-definitive-evidence-for-infarction-with-multivessel-disease/" title="Read more" >...</a>

ESC 2019 | POPULAR AGE: el viejo clopidogrel sigue teniendo su lugar

ESC 2019 | POPULAR AGE: Good Old Clopidogrel Still Valid

According to this study, presented during the ESC 2019 scientific sessions, non-ST acute coronary syndrome (NSTE-ACS) patients treated with ticagrelor presented a significantly higher risk of bleeding than patients treated with clopidogrel, with no counterbalance by higher benefit in thrombotic events. Researchers suggest clopidogrel might be the gold standard for this elderly NSTE-ACS population, though<a href="https://solaci.org/en/2019/09/03/esc-2019-popular-age-good-old-clopidogrel-still-valid/" title="Read more" >...</a>